Pharmaceutical company Dr. Reddy's Laboratories Ltd (BSE:500124) (NSE:DRREDDY) (NYSE:RDY) reported on Wednesday the availability of Atomoxetine Capsules, USP in the US market.
In addition, the company's Atomoxetine Capsules, USP is available in 10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg, 100 mg with 30 counts bottle size. Atomoxetine is used to treat attention-deficit hyperactivity disorder (ADHD), including psychological, social, and other treatments. It may help to increase the ability to pay attention, concentrate, stay focused and stop fidgeting.
The company said the US Food and Drug Administration (USFDA) approved Atomoxetine Capsules, USP, is the therapeutic equivalent generic version of Strattera (atomoxetine) Capsules. Straterra is a registered trademark of Eli Lilly and Company.
For the most recent 12 months ending in August 2018, the Strattera brand and generic had US sales of about USD304m MAT, according to IMS Health.
Lannett Company signs contract with Elite Pharmaceuticals and SunGen Pharma
PDL BioPharma unveils authorised generic Tekturna (aliskiren) in the US
Breckenridge wins final US FDA approval for Imatinib Mesylate Tablets ANDA
Teva Launches Authorized Generic of Flector Patch in the United States
Breckenridge awarded US FDA's final approval for Exemestane Tablets (Aromasin) ANDA
Mylan unveils generic Suboxone Sublingual Film for treating opioid dependence
Indivior's US affiliate launches authorised generic version of Suboxone
Alvogen unveils generic Suboxone (Buprenorphine/Naloxone) sublingual film